1. Home
  2. LDI vs MNPR Comparison

LDI vs MNPR Comparison

Compare LDI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$1.01

Market Cap

607.4M

Sector

Finance

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$109.87

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
MNPR
Founded
2010
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
607.4M
587.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
LDI
MNPR
Price
$1.01
$109.87
Analyst Decision
Sell
Strong Buy
Analyst Count
3
11
Target Price
$3.00
$107.00
AVG Volume (30 Days)
1.9M
210.1K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.58
N/A
Revenue Next Year
$13.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$29.18
52 Week High
$5.05
$116.64

Technical Indicators

Market Signals
Indicator
LDI
MNPR
Relative Strength Index (RSI) 36.43 62.67
Support Level N/A $52.92
Resistance Level $1.32 $112.57
Average True Range (ATR) 0.07 8.75
MACD -0.01 -0.80
Stochastic Oscillator 29.45 67.27

Price Performance

Historical Comparison
LDI
MNPR

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: